All In Biotech

Drug Trial Radar · NCT02573844

Pain Relief In Irritable Bowel Syndrome

Efficacy of Proklama on Patients' Symptoms With Irritable Bowel Syndrome: Clinical Trial, Double- Blind, Crossover, Controlled Study vs. Placebo

Last checked: Nov 20, 2026Latest source record: Aug 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 2015

Primary completion

Oct 2017

Study completion Jun 2018

Sponsor

Lead sponsor
Geophyt S.r.l.s.Industry
Sponsor type
Industry
First posted
Oct 12, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Proklama is effective in significative reduction of pain, other symptoms IBS's related, and improves quality of life concerning IBS disease.

Conditions

  • Irritable Bowel Syndrome

Interventions

  • ProklamaDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recorded pain in a diary using a 11-points Numeric Rating Scale (NRS)Time frame: 24 h

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Policlinico San Matteo Pavia Fondazione IRCCS

    Pavia, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.